The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.
[EN] FGFR2 MODULATORS<br/>[FR] MODULATEURS DE FGFR2
申请人:EXELIXIS INC
公开号:WO2012061337A1
公开(公告)日:2012-05-10
A compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein:R3a, R2, R3b, R4b, L1, G and J are as defined in the specification, pharmaceutical compositionsthereof, and methods of use thereof.
[EN] HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROARYLES UTILES EN TANT QU'INHIBITEURS DE KINASE RAF
申请人:BIOGEN IDEC INC
公开号:WO2010078408A1
公开(公告)日:2010-07-08
The present invention provides compounds of formula (I) useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf -mediated diseases.
The invention is related to compounds of formula (I) as antagonists of the TGFβ family type I receptors, Alk5 and/or AIk 4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGFβ family signaling activity is desirable.
[EN] SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE<br/>[FR] BENZAZOLES SUBSTITUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA RAF KINASE
申请人:CHIRON CORP
公开号:WO2005037273A1
公开(公告)日:2005-04-28
New substituted benzazole compounds of formula (I), compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.